Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 27, 2016 16:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the 35th Annual J.P. Morgan Healthcare Conference

BERKELEY, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present...
December 06, 2016 05:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Europe’s Hans van Eenennaam, Ph.D. and John Dulos, Ph.D. Honored with the Intellectual Property Owners Education Foundation’s 43rd Inventor of the Year Award for Contributions in the Discovery of KEYTRUDA® (pembrolizumab)

BERKELEY, Calif. and OSS, The Netherlands, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies,...
December 05, 2016 04:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD

Expected Filing of Investigational New Drug (IND) Application in 2017 Company to Host Conference Call Today to Provide Program Update, Including STELLAR, at 5:30 a.m. PT/ 8:30 a.m. ET ...
December 03, 2016 12:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma

BERKELEY, Calif. and OSS, The Netherlands, Dec. 03, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today...
November 21, 2016 08:00 ET | Source: Aduro Biotech, Inc.

Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech LADD Clinical Trials

BERKELEY, Calif., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the U.S. Food...
November 12, 2016 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase 1b Mesothelioma Clinical Trial

Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Continues to Show Clinical Activity of CRS-207 Two Additional Poster Presentations Detailing Promising Preclinical...
November 09, 2016 16:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech’s Personalized LADD Therapy Featured in an Oral Presentation at SITC’s New Cancer Immunotherapy Agents in Development Program

BERKELEY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced that Tom Dubensky Jr.,...
November 07, 2016 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Presents Preclinical Data Demonstrating Acute and Systemic Immune Activation through STING Pathway Stimulation with ADU-S100

BERKELEY, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today highlighted an oral presentation given by the company’s chief scientific officer, Thomas Dubensky Jr.,...
November 02, 2016 16:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Reports Third Quarter 2016 Financial Results

BERKELEY, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the third quarter 2016. Net loss for the three months ended September 30,...
October 24, 2016 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Reports Partial Clinical Hold to Pause Enrollment in LADD Trials

--Current Clinical Trial Patients Are Continuing to Receive LADD Treatment-- --Company to Host Conference Call Today at 6 a.m. PT/9 a.m. ET-- BERKELEY, Calif., Oct. 24, 2016 (GLOBE...